Loading...
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved patients’ outcomes and paved the way for the beginning of advent of targeted approaches in breast ca...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Research Foundation
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3376449/ https://ncbi.nlm.nih.gov/pubmed/22720269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2012.00062 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|